Mifamurtide
Also known as: CGP-19835A, L-MTP-PE, Mepact, Mifamurtide, MTP-PE, MTP‑PE, Muramyl tripeptide phosphatidylethanolamine
Source Mifamurtide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Mifamurtide (muramyl tripeptide phosphatidylethanolamine) is a lipophilic derivative of bacterial muramyl dipeptide used as an adjuvant therapy for resectable high‑grade osteosarcoma.
Mechanism of Action
Activates NOD2 receptors on monocytes/macrophages, triggering NF-κB signaling and cytokine release that enhances anti‑tumor immune responses.
Routes of Administration
Goals & Uses
- Adjuvant treatment of high‑grade osteosarcomaOncologyModerate
- Immunostimulation / macrophage activationImmunologyModerate
- Prevention of metastatic relapseOncologyModerate
- Osteosarcoma adjuvant treatmentOncologyHigh
- Investigational use in other sarcomasOncologyLow
Contraindications
- Severe active infectionsInfectionModerate
- Hypersensitivity to mifamurtide or liposomal componentsAllergyHigh
- Known hypersensitivity to mifamurtide or its excipientsAllergyHigh
- Concurrent high-dose NSAIDs or corticosteroidsDrug InteractionHigh
- Concurrent use of cyclosporine or other calcineurin inhibitorsDrug InteractionHigh
- Active autoimmune or inflammatory disease requiring immunosuppressionDisease StateModerate
Adverse Effects
- Anemia / thrombocytopeniaHematologicUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularUncommonLow blood pressure
- Fever and chillsConstitutionalCommon
- Nausea and vomitingGastrointestinalCommon
- Tachycardia and hypertensionCardiovascularUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- Injection‑site reactionsLocalCommon
- Chills / rigorsSystemicCommon
- FeverSystemicCommonElevated body temperature
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, azathioprine)Moderate
- Corticosteroids (high-dose)High
- Live vaccinesModerate
- CyclosporineHigh
- NSAIDsModerateMay increase renal risk in susceptible patients
- Doxorubicin / Cisplatin / MethotrexateLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Adults over 30 yearsAgeRelative
- Patients with severe hepatic or renal impairmentOrgan ImpairmentRelative
- Patients with active infectionsInfectious DiseaseRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Children under 2 yearsPediatricRelative
- Patients ≥2 years old with resectable high‑grade osteosarcomaIndicationAbsolute
Regulatory Status
- European UnionApprovedApproved: adjuvant treatment of high‑grade osteosarcoma post‑surgeryMarketed as Mepact.
- United StatesUnapprovedInvestigational; not FDA‑approved.
- United KingdomApprovedApproved: adjuvant treatment of high‑grade osteosarcomaRegulated under EU framework post‑Brexit.
Approved in the European Union (Mepact) for post‑surgical osteosarcoma; not approved in the United States, where it remains investigational.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Mifamurtide?
Mifamurtide (muramyl tripeptide phosphatidylethanolamine) is a lipophilic derivative of bacterial muramyl dipeptide used as an adjuvant therapy for resectable high‑grade osteosarcoma.
What is Mifamurtide used for?
Mifamurtide is educationally associated with: Adjuvant treatment of high‑grade osteosarcoma, Immunostimulation / macrophage activation, Prevention of metastatic relapse, Osteosarcoma adjuvant treatment, Investigational use in other sarcomas. Educational only — not medical advice.
How is Mifamurtide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Mifamurtide?
Reported adverse effects include: Anemia / thrombocytopenia, Headache, Hypotension, Fever and chills, Nausea and vomiting, Tachycardia and hypertension, Nausea, Fatigue, Injection‑site reactions, Chills / rigors, Fever. This list is not exhaustive — consult a qualified clinician.
Who should avoid Mifamurtide?
Recorded contraindications: Severe active infections, Hypersensitivity to mifamurtide or liposomal components, Known hypersensitivity to mifamurtide or its excipients, Concurrent high-dose NSAIDs or corticosteroids, Concurrent use of cyclosporine or other calcineurin inhibitors, Active autoimmune or inflammatory disease requiring immunosuppression. Consult a qualified clinician before use.